PF-219,061
PF-219,061
PF-219,061 (pronunciation: P-F-two-one-nine-zero-six-one) is a pharmaceutical compound currently under investigation for its potential therapeutic applications.
Etymology
The name "PF-219,061" is a proprietary designation given by the pharmaceutical company Pfizer. The "PF" stands for Pfizer, while "219,061" is a unique identifier for this specific compound within the company's research and development pipeline.
Description
PF-219,061 is a novel small molecule compound. It is part of a class of drugs known as kinase inhibitors, which work by blocking the action of a specific type of enzyme known as a kinase. This can help to regulate cell growth and division, making kinase inhibitors potentially useful in the treatment of certain types of cancer and other diseases.
Related Terms
- Pfizer: The pharmaceutical company responsible for the development of PF-219,061.
- Kinase inhibitor: A type of drug that PF-219,061 belongs to.
- Small molecule: A low molecular weight organic compound that is often used as a drug or drug candidate.
- Cancer: A group of diseases characterized by the uncontrolled growth and spread of abnormal cells, which kinase inhibitors like PF-219,061 may be used to treat.
External links
- Medical encyclopedia article on PF-219,061
- Wikipedia's article - PF-219,061
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski